| Drug Name |
Alectinib |
| Drug ID |
BADD_D02480 |
| Description |
Alectinib is a second generation oral drug that selectively inhibits the activity of anaplastic lymphoma kinase (ALK) tyrosine kinase. It is specifically used in the treatment of non-small cell lung cancer (NSCLC) expressing the ALK-EML4 (echinoderm microtubule-associated protein-like 4) fusion protein that causes proliferation of NSCLC cells. Inhibition of ALK prevents phosphorylation and subsequent downstream activation of STAT3 and AKT resulting in reduced tumour cell viability.
Approved under accelerated approval in 2015, alectinib is indicated for use in patients who have progressed on or were not tolerant of crizotinib, which is associated with the development of resistance. |
| Indications and Usage |
Alectinib is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. |
| Marketing Status |
approved; investigational |
| ATC Code |
L01ED03 |
| DrugBank ID |
DB11363
|
| KEGG ID |
D10542
|
| MeSH ID |
C582670
|
| PubChem ID |
49806720
|
| TTD Drug ID |
D0U3SY
|
| NDC Product Code |
69988-0047 |
| UNII |
LIJ4CT1Z3Y
|
| Synonyms |
alectinib | Alecensa | CH5424802 | RO5424802 |
